Digitalis glycosides: mechanisms and manifestations of toxicity. Part III.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000175:diagnosis / Q000628:therapy; D002792:Cholestyramine Resin / Q000627:therapeutic use; D004071:Digitalis Glycosides / Q000009:adverse effects / Q000097:blood / Q000276:immunology / Q000506:poisoning*; D004342:Drug Hypersensitivity / Q000209:etiology; D004554:Electric Countershock / Q000379:methods; D004562:Electrocardiography; D004700:Endocrine System Diseases / Q000139:chemically induced; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006329:Heart Conduction System / Q000187:drug effects; D006464:Hemoperfusion; D006801:Humans; D007008:Hypokalemia / Q000139:chemically induced; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage; D007074:Immunoglobulin G / Q000008:administration & dosage; D008012:Lidocaine / Q000627:therapeutic use; D008297:Male; D009422:Nervous System Diseases / Q000139:chemically induced; D010672:Phenytoin / Q000627:therapeutic use; D011188:Potassium / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D006435:Renal Dialysis; D012735:Sexual Dysfunction, Physiological / Q000139:chemically induced; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors; D014700:Verapamil / Q000627:therapeutic use; D014786:Vision Disorders / Q000139:chemically induced
D000319:Adrenergic beta-Antagonists; D000906:Antibodies; D004071:Digitalis Glycosides; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D002792:Cholestyramine Resin; D010672:Phenytoin; D008012:Lidocaine; D014700:Verapamil; D000254:Sodium-Potassium-Exchanging ATPase; D011802:Quinidine; D011342:Procainamide; D011188:Potassium